Advertisement

Glucose variability in PD-1 inhibitors-induced diabetes mellitus

  • Francesco Tassone
  • Elena Gamarra
Letter to the Editor
  • 32 Downloads

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Human and animal rights disclosure

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

References

  1. 1.
    Marchand L, Thivolet A, Dalle S, Chikh K, Reffet S, Vouillarmet J et al (2018) Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol.  https://doi.org/10.1007/s00592-018-1234-8 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tassone F, Colantonio I, Gamarra E, Gianotti L, Baffoni C, Magro G et al (2018) Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring. Acta Diabetol 25:1–2.  https://doi.org/10.1007/s00592-018-1246-4 Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes and MetabolismSanta Croce and Carle HospitalCuneoItaly

Personalised recommendations